| Paringa Resources (NASDAQ: PNRL) Reports Quarterly Sales of $5.7M |
| |
|
Paringa Resources (NASDAQ: PNRL), operator of the low cost, high quality Poplar Grove coal mine in western Kentucky, reported $5.7 million in sales for the quarter ended September 30.
Why It Matters: PNRL is now operating at a $23 million annual revenue run rate. Coal shipped for the September quarter totaled 136K tons, up from 26K tons in the June quarter. Western Kentucky coal markets are almost entirely domestic sales to utilities for power generation, underpinned by demand for power from large-scale manufacturing and industry in the region. PNRL is now shipping coal to both of its major customers, and maintains a very strong pipeline of forward sales, with ~100% of 2019, ~75% of 2020 and ~50% of the next 5 years' production pre-sold.
The Backstory: PNRL is an undiscovered, low-cost coal producer. PNRL will operate at the low end of its regional cost curve because it has simple operations and a skilled, non-union workforce in a very mining-friendly jurisdiction and low-cost barge transportation to customers. PNRL has fixed-price contracts with regulated, investment-grade utilities with over 80% of all coal pre-sold through the end of 2020, and 50% of the next five-years’ production under contract, providing high certainty for short and medium-term cash flow. In addition, the company is assessing plans to develop the shovel-ready, fully permitted Cypress Mine. Roth Capital Partners and HC Wainwright cover the stock with Buy ratings and $33 and $13 price targets, respectively. PNRL trades at a low relative valuation based on forecast cashflows for Poplar Grove, with projected EV / EBITDA (2021) of 1.9x, substantially below Alliance Resource Partners (NASDAQ: ARLP), a major regional competitor.
Disclosure
Paringa Resources Limited (NASDAQ: PNRL) is a client of RedChip Companies, Inc. PNRL agreed to pay RedChip Companies, Inc., a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| Cyclo Therapeutics (OTCQB: CTDH) Announces EU Coordinating Investigator for Pivotal NPC Trial |
| |
|
Cyclo Therapuetics (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced that Professor Maurizio Scarpa, MD, PhD, Director of the Regional Coordinating Center for Rare Disease, Udine University Hospital, Udine, Italy and Professor of Pediatrics, University of Padova, Italy, will serve as EU Coordinating Investigator for the company’s upcoming Phase III pivotal trial in Niemann Pick Disease Type C.
Why It Matters: Dr. Scarpa is also expected to serve as site director of the Udine Hospital program in the pivotal trial. The company is currently designing the global Phase III pivotal trial in NPC. The EU Coordinating Investigator role is required by EU regulatory authorities for studies that will lead to Market Approval Applications involving more than one EU member state.
Key Quote: “Dr. Scarpa brings to this role not only his deep clinical trial expertise and commitment to helping NPC patients, but he also brings a willingness to work across Europe through his many contacts to assist in patient recruitment for the full study. We look forward to working with Dr. Scarpa in this new capacity.” - Scott Fine, Chairman & CEO
The Backstory: CTDH is currently completing enrollment of its Phase I/II trial on NPC in Europe and Israel, with Dr. Reena Sharma as EU Coordinating Investigator (See ClinicalTrials.gov NCT 02912793). Dr. Sharma is Senior Consultant in Metabolic Disorders at the Salford Royal Foundation Trust Hospital, Salford, UK, and is a site director for the trial at Salford. Approved sites for the Phase I/II trial are in the UK (three sites), Sweden (1 site), Italy (1 site) and Israel (2 sites). Dr. Sharma will serve as the EU Coordinating Investigator for the Extension Protocol for the current trial.
Disclosure
Cyclo Therapeutics, Inc. (OTCQB: CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) Accelerating Lithium Hydroxide Strategy |
| |
|
Piedmont Lithium (NASDAQ: PLL), an emerging lithium company focused on the development of its 100%-owned Piedmont Lithium Project in North Carolina, is accelerating development of its lithium chemical plant and is compressing its Project timeline into a single-stage targeting lithium chemical production in late-2022.
Why It Matters: This new timeline will effectively accelerate chemical plant development by one year while deferring the mine/concentrator construction start date by one year, resulting in integrated operations from day one. This integration should lead to improved project economics given the higher margins associated with the lithium chemical business, while eliminating spodumene concentrate sales into the Chinese market.
Key Quote: “Over the past several months we have engaged in encouraging dialogue with prospective customers throughout the lithium supply chain. Themes that are common to all the discussions are: (a) the dramatic growth in lithium hydroxide required to support the EV platforms currently being developed; (b) the strong desire of lithium customers to diversify their supply sources away from the dominant China market; and (c) the concrete plans of selected parties to aggressively develop their battery supply chains in the United States and Europe. Nobody is better positioned than Piedmont Lithium to capitalize on these developments.” – Keith Phillips, President & CEO
The Backstory: Location is one of the standout features of the Piedmont project, with access to excellent infrastructure and transport options, close proximity to existing lithium chemical processing facilities operated by Livent (NYSE: LTHM) and Albemarle (NYSE: ALB), and within reach of 13 auto manufacturing facilities. Compared to Australian- and Canadian-based projects, North Carolina offers a significantly lower-cost operating environment (labor, power/gas/diesel, transport), which is further boosted by the absence of government royalties and a low tax rate environment. Lithium is on the US Government’s Critical Minerals list, giving the project significant strategic value as being the only conventional US lithium development project. Vertically integrated hard rock / chemical projects generate substantially higher operating margins and EBITDA numbers than either independent miners selling 6% spodumene concentrate (“SC6.0”) to chemical converters in China (i.e. Alliance, Altura and Pilbara) or Chinese converters sourcing SC6.0 at market prices from Australian miners (i.e. Ganfeng, Tianqi).
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| cbdMD (NYSE American: YCBD) Launches Save Mart Partnership |
| |
|
cbdMD (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, announced its partnership with Save Mart in Modesto, CA, a retailer which operates 207 traditional and price impact stores under the banners of Save Mart, Lucky, Lucky California, FoodMaxx, S-Mart Foods, and Maxx Value Foods. The launch was celebrated on Saturday, October 12, with an appearance by Team cbdMD athlete, former UFC Champion and current Bellator MMA fighter, Quinton "Rampage" Jackson.
Why It Matters: The cbdMD partnership with the Save Mart location in Modesto, CA allows this location to be the first Save Mart to provide CBD offerings to their customers. With 26 different cbdMD products available for purchase, consumers can choose from a wide array of tinctures, topicals, capsules, bath bombs and Paw cbd pet products.
Key Quote: “Save Mart has been providing their customers with premium products since 1952. At cbdMD, we are honored to partner with them to continue their legacy.” – Pancho Mangual, EVP
The Backstory: cbdMD is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and CBD pet products. cbdMD is also the proud partner with the BIG3 Basketball League, Barstool Sports, Bellator MMA, Life Time, Inc. and Nitro Circus. cbdMD has one of the largest rosters of professional sports athletes who are part of "Team cbdMD."
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| Immuron (NASDAQ: IMRN) Reports North American Sales Up 111% YoY |
| |
|
Immuron (NASDAQ: IMRN), which focuses on developing oral immunotherapies for the prevention and treatment of gut-mediated pathogens, announced sales results for its commercially available, over-the-counter gastrointestinal and digestive health supplement Travelan®, for the quarter ended September 30, 2019, of fiscal year 2020 (Q1).
Why It Matters: Total North American sales for Travelan® were up 111% compared to the same period last year and reached $269K* AUD, marking a solid start to the fiscal year. In the US, Q1 sales grew 81% year on year (YoY) to $232K* AUD, primarily due to continued expansion via our programs with Passport Health Travel Clinics, Medique and Medico Mart. Amazon sales of Travelan through Medique continue to remain strong. In Canada, Q1 sales reached $38K* AUD, with Travelan now being sold in Shoppers Drug Mart, Jean Coutu, and selected independent pharmacies in addition to Amazon.ca.
Key Quote: “The sales momentum for Travelan® which was already evident in fiscal year 2019 has continued strongly into the first quarter of fiscal year 2020 as consumer awareness of Travelan® continues to grow.” – Dr. Gary Jacob, CEO
The Backstory: Led by Dr. Gary S. Jacob, founding CEO of Synergy Pharmaceuticals and co-inventor of TRULANCE® (an FDA-approved drug), who joined the board and became CEO in November 2018, Immuron has an immediate focus on seeking FDA approval of Travelan® to treat TD. According to the Centers for Disease Control and Prevention (CDC), an estimated 10 million international travelers develop TD every year. Approval of Travelan® to treat TD is expected to significantly increase commercial opportunities for Travelan® in the U.S. and in Canada, particularly as Travelan® is a non-antibiotic treatment having a considerable record of successful treatment. Revenue generated from Travelan® has consistently grown over the past few years.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Can Fite (NYSE American: CANF) Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine |
| |
|
Can Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International Journal of Molecular Medicine has published a study titled “The A3 adenosine receptor agonist, namodenoson, ameliorates non alcoholic steatohepatitis in mice.”
Link to abstract: www.spandidos-publications.com/10.3892/ijmm.2019.4364
Why It Matters: The comprehensive study tested the effects of Namodenoson on two different NASH models and on a cell line of human liver cells, resembling the metabolic phenotype observed in NASH patients. The study data show that Namodenoson induced significant anti inflammatory, anti steatotic and anti fibrotic effects mediated by de-regulation of the Wnt/β-catenin pathway, known to be active in NAFLD/NASH.
Key Quote: “The growing amount of data showing Namodenoson’s liver protective properties is highly encouraging as the Phase II clinical study in NASH nears completion. Namodenoson can potentially serve a clear and unmet need, as the U.S. FDA has yet to approve a drug specifically to treat NAFLD and NASH. We are pleased to work with Can-Fite on this study and hope to show similar data in the patients.” – Dr. Rifaat Safadi
The Background: CANF is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (NYSE American: CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of RedChip investor awareness services and consulting services. RedChip Companies also owns 16,500 shares of CANF Rule 144 stock, acquired in August 2019.
|
|
| |
|
| SinglePoint (OTCQB: SING) Launches Pure American Hemp™ Cigarettes; Catching Fire at NACS |
| |
|
SinglePoint (OTCQB: SING), a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration, announced that it sold multiple cases of Pure American Hemp™ Cigarettes to retail store owners representing approximately 2500 stores at the 2019 National Association of Convenience Stores show (NACS) in Atlanta.
Why It Matters: With the passage of the 2018 Farm Bill and the mainstreaming of CBD hemp flower, the market for innovative products such as hemp cigarettes is growing rapidly. There is a significant need for reliable suppliers with the capacity to move product. Its demonstrated capacity to deliver has established SinglePoint as one of the dominant players in the CBD and hemp marketplace.
Key Quote: “Our success at NACS was beyond what anybody in our group imagined. It truly gave us deep insight to how large of an opportunity this is. Over the next 90 days we will be following up with these owners to finalize their purchase orders. I am ecstatic to say that again we had people waiting in line to speak about our hemp cigarettes. It reminded me of the successful product introduction of Premium Cigars International and PrimeTime™ to the convenience store industry. We expect this new product to dramatically increase revenue in the near future.” - Greg Lambrecht, CEO
The Background: BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 while New York-based investment bank Cowen & Co. estimates that the market could pull in $15 billion by 2025. The smokable hemp market currently represents approximately 2% of the overall CBD market, but with a 250% growth from 2017 to 2018. Brightfield Group, a Chicago-based cannabis market research firm, identifies dried and smokable hemp flowers as one of the fastest-growing segments of the CBD market.
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services
|
|
| |
|
| |
| Quote of the Week |
| |
"Invest in something you can get your arms around and be very conservative, own enough stock so that you are not putting all your eggs in one basket."
-Dave Maley, Manager of Ariel Microcap Funds-Microcap Superstar |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
